Sugi Predict

Sugi Predict / Compounds / SCHEMBL18924937

SCHEMBL18924937

SCHEMBL18924937

CNc1ncnc(C(=O)N2CCC(N3CCC(N(C)S(C)(=O)=O)CC3)CC2)c1C

nearest known ligand 0.59

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CCR2 P41597 3/20 0.59
▸ CCR5 P51681 5/20 0.44
▸ L3MBTL3 Q96JM7 2/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ CCRL2 O00421 1/20 0.37
▸ HRH1 P35367 3/20 0.35
▸ CCR3 P51677 3/20 0.35
▸ IRAK4 Q9NWZ3 2/20 0.34
▸ SYK P43405 1/20 0.34
▸ LRRK2 Q5S007 1/20 0.33
▸ GPR119 Q8TDV5 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21422756 0.90 CCR2 (0.71) CCR2CCR5L3MBTL3L3MBTL1HRH1
SCHEMBL13346806 0.87 CCR2 (0.58) CCR2CCR5L3MBTL3L3MBTL1HRH1
SCHEMBL2745143 0.87 CCR2 (0.58) CCR2CCR5L3MBTL3L3MBTL1HRH1
SCHEMBL10179127 0.86 CCR2 (0.58) CCR2CCR5L3MBTL3L3MBTL1CCRL2
SCHEMBL10179237 0.86 CCR2 (0.58) CCR2CCR5L3MBTL3L3MBTL1CCRL2
SCHEMBL21422747 0.86 CCR2 (0.46) CCR2CCR5L3MBTL3L3MBTL1HRH1
SCHEMBL10231671 0.86 CCR2 (0.57) CCR2CCR5L3MBTL3L3MBTL1CCRL2
SCHEMBL10232156 0.86 CCR2 (0.59) CCR2CCR5L3MBTL3L3MBTL1CCRL2
SCHEMBL10229961 0.85 CCR2 (0.59) CCR2CCR5L3MBTL3L3MBTL1CCRL2
SCHEMBL10178558 0.85 CCR2 (0.72) CCR2CCR5L3MBTL3L3MBTL1CCRL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731981-B2 CCR2 receptor antagonists and uses thereof CENTREXION THERAPEUTICS CORPORATION (US) 2023-08-22 — — US disclosed
US-20220002310-A1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT 2022-01-06 — — US disclosed
US-11046706-B2 CCR2 receptor antagonists and uses thereof CENTREXION THERAPEUTICS CORPORATION (US) 2021-06-29 — — US disclosed
US-20190300541-A1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT 2019-10-03 — — US disclosed
US-9670222-B2 CCR2 receptor antagonists and uses thereof CENTREXION THERAPEUTICS CORPORATION (US) 2017-06-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300541-A1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF CCR2, CCRL2, CCR1 CCR2 1/4885CCR5 5/4885L3MBTL3 3778/4885
US-11046706-B2 CCR2 receptor antagonists and uses thereof CCR2, CCRL2, CCR1 CCR2 1/4885CCR5 5/4885L3MBTL3 3778/4885
US-11731981-B2 CCR2 receptor antagonists and uses thereof CCR2, CCRL2, CCR1 CCR2 1/4885CCR5 5/4885L3MBTL3 3778/4885
US-20220002310-A1 CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF CCR2, CCRL2, CCR1 CCR2 1/4885CCR5 5/4885L3MBTL3 3778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.